No risk association observed for anthracycline chemotherapy, cognitive decline

New data analyses found no association between anthracycline chemotherapy and greater risk of cognitive decline in breast cancer survivors, according to an article. Possible adverse effects of breast cancer treatment on cognitive function have been acknowledged but the risks of specific chemotherapies remain undetermined.